Quick Verdict: Ray Blanco is a real, long-tenured newsletter editor who has published under Agora Financial and now Paradigm Press since 2010. He’s not a fake persona, and his research is genuinely written by him. But subscriber feedback on value for price is mixed, and his marketing leans heavily on urgency and bold guarantees. This review is for anyone who got a Ray Blanco ad in their inbox and wants to know who he actually is before they subscribe to anything.
Looking for more information about Ray Blanco’s FDA Profit Alert? I’ve researched it to find out more and put together an honest FDA Profit Alert Review, containing everything you need to know about Ray Blanco’s FDA Profit Alert research and his Flash Approval Indicator.
Who Is Ray Blanco?
Ray Blanco holds a bachelor’s degree in information technology from Hodges University. Before he became a newsletter editor, he spent more than a decade working as a network technician and systems analyst, including a stretch at a private wealth management firm that managed over $30 billion in client assets. That background is where his “tech-meets-markets” angle comes from; he built systems for investment firms before he started writing about the stocks those firms trade.
Blanco joined Seven Figure Publishing (part of the Agora Financial network) in 2010. Over the years, he’s edited a rotating list of newsletters, including Technology Profits Confidential, Breakthrough Technology Alert, FDA Trader (later marketed as FDA Profit Alert), Technology Profits Daily, and Penny Pot Profits. In 2019, his closed positions in Technology Profits Confidential reportedly beat the S&P 500 by 50%, a figure that comes from the publisher’s own marketing, so treat it as a claim to weigh rather than an audited result.
Today, Blanco publishes primarily through Paradigm Press, an Agora Financial imprint based in Baltimore, Maryland. He’s based in Naples, Florida. His two main active services are Technology Profits Confidential and Ray Blanco’s Catalyst Trader, and he also co-edits the Paradigm Mastermind Group alongside Jim Rickards and James Altucher.
Ray Blanco Services
Blanco has put his name on quite a few newsletters over the years. Here’s a short breakdown of the ones that matter most right now:
Technology Profits Confidential
His flagship service. A monthly newsletter covering emerging tech stocks, from AI to biotech to clean energy, plus a model portfolio and periodic trade alerts.
Ray Blanco’s Catalyst Trader
A faster-paced trading service built around “catalyst” events, mostly FDA decisions and drug trial data in the biotech sector. This is the direct successor to FDA Trader, which was also marketed for a time as FDA Profit Alert (more on that below).
Paradigm Mastermind Group
A joint service with Jim Rickards and James Altucher, currently focused on artificial intelligence stock opportunities.
Penny Pot Profits
A legacy service that focused on cannabis stocks. This one appears to be discontinued.
Biotech is the most valuable thing in the world. There will come a time when Apple will run out of iSomething ideas for you to buy every year. But nobody ever gets tired of life and being healthy; it’s the most valuable thing there is.
People’s lives will be saved tomorrow because of good people working hard to mine the secrets of the natural world today. Plus, there’s lots of money to be made doing it.
You see, the biotech sector has something that other fields don’t have: catalysts. Actual triggers that can help us determine whether the “next big thing” will be just that. It’s all about finding the best triggers, at the right time, to make the most profit and walk away with the best gains possible. As they say, timing is everything.
In biotech, there’s an investment cycle: get in too early, and you lose money. Get in too late, and the money’s been made.
But find the right catalyst and sell at the right time, and you can earn multiples of your original investment.
In FDA Profit Alert, Ray Blanco used a proprietary Flash Approval Indicator, which the marketing claimed could flag major FDA drug approvals ahead of the announcement. That branding is largely retired now; the same catalyst-trading approach lives on today under Ray Blanco’s Catalyst Trader, which still centers on FDA decision dates and other biotech news events. If you signed up under the FDA Profit Alert name, you were likely rolled into this successor service. The pitch behind it was straightforward: when Ray Blanco’s indicator starts to spike, he believes a big profit opportunity is imminent, and a company on the verge of an FDA decision could move quickly once the news breaks.
What Was Included With an FDA Profit Alert Subscription
Here’s what subscribers received under the original offer:
- New Issue and Trade Alerts Nearly Every Week: In addition to the weekly newsletter summarizing that week’s trades, new FDA approvals are announced all the time, and whenever Blanco’s indicator flagged one, subscribers received an email alert with entry details. A second alert followed when it was time to close a trade.
- A digital report titled Your First Flash Approval Trade: Get In Now, And You Could Pocket Big Gains.
- A digital beginner’s guide, Getting Started With The Flash Approval Indicator.
- Optional text alert updates.
- A free Kindle tablet, offered only to yearly subscribers.
- A ticket to a virtual Biotech Profit Symposium.
FDA Profit Alert Pricing
At the time the FDA Profit Alert offer ran, pricing was set at $1,995 for one year or $595 for three months. Newsletter pricing changes often, and publishers frequently run promotional discounts off these list prices. If you’re looking at a current offer for Ray Blanco’s Catalyst Trader or another active service, confirm the exact price and terms on the order page before you pay; don’t rely on older figures like these.
Is There a Guarantee or Refund Policy?
The subscription was backed by what the publisher called the FDA Ironclad Profit Guarantee, available only to yearly subscribers. The pitch: if you didn’t get the chance at 20 or more 500%+ winners within 12 months, you could call and receive lifetime access to the service at no extra cost. Guarantees like this are common in the newsletter industry and are usually structured around getting access to more research rather than a cash refund, so read the exact terms carefully before you count on one.
Track Record
Newsletter track records in this space are hard to verify independently because most performance figures come from the publisher rather than an outside auditor. Here’s what’s publicly available:
Blanco’s publisher has stated that his closed Technology Profits Confidential positions beat the S&P 500 by 50% in 2019. Subscriber-reported results are mixed. On third-party review site Stock Gumshoe, Ray Blanco’s Catalyst Trader (the successor to FDA Trader) carries a subscriber rating of roughly 2.3 out of 5 stars based on over 40 votes, with individual category scores in a similar range. Some readers have reported solid short-term wins on individual picks; others say the service hasn’t lived up to the marketing.
One reviewer on an independent review site described a run of winning trades over six months. Other subscribers, in comments on Stock Gumshoe and elsewhere, describe disappointment with specific picks or with how the “catalyst” timing played out. As with most speculative trading newsletters, individual results vary a lot depending on which alerts you acted on and when.
Within minutes of joining the FDA Profit Alert group, subscribers received the urgent report Your First Flash Approval Trade: Get In Now, And You Could Pocket Big Gains, walking them through the situation Blanco’s indicator had flagged at the time. That kind of same-day urgency is a consistent theme across Blanco’s marketing and is worth factoring into your decision; it’s a sales technique as much as it’s a research signal.
Pros and Cons
Pros:
- Blanco is a real, verifiable editor with a long track record at an established publisher, not an anonymous or fake persona
- Research write-ups are detailed, with plain-language rationale behind each pick
- Regular news flow (FDA decisions happen most months) keeps the service active with fresh alerts
- Some subscribers report solid short-term gains on individual picks
Cons:
- Subscriber ratings on independent review sites sit below the newsletter industry average
- Marketing leans heavily on urgency and bold guarantees that don’t always match the pace of actual alerts
- Billing is auto-renewing, and for at least one service, canceling means logging into PayPal directly rather than contacting support
- Performance figures largely come from the publisher rather than an independent audit
Is Ray Blanco Legit?
Yes, in the sense that matters most: Ray Blanco is a real person with a documented, decade-plus career at Agora Financial and now Paradigm Press, and the research behind his newsletters is his own rather than a ghostwritten front. He is not running a fake identity or a disappearing operation; Paradigm Press is an established publisher with a public office and other well-known editors under the same roof.
Where you should stay cautious is the marketing style and the return claims. Phrases like “Ironclad Profit Guarantee” and promises of 500%+ winners are attention-grabbing sales copy, and subscriber ratings on independent sites sit below average for the newsletter industry. Treat any specific stock pick as one analyst’s speculative opinion, not a guarantee, and never invest money you can’t afford to lose.
When the FDA approves a new drug, it sends stocks soaring, and by getting ahead of these big moves, you could walk away with meaningful gains. But that upside comes with real risk; small biotech stocks tied to a single FDA decision can also fall hard if the news goes the other way, so this kind of trading suits investors who are comfortable with high volatility, not conservative or first-time investors.
With the FDA approving several new drugs each month, there’s a steady news flow for a catalyst-focused service to work with. As a subscriber to a service like Ray Blanco’s Catalyst Trader, you’d get Blanco’s read on upcoming FDA decisions along with his suggested entry and exit points.
FAQs
Who publishes Ray Blanco’s research?
Paradigm Press, which operates under the same umbrella as Agora Financial, a Baltimore-based financial publishing company that’s been in business for decades. Some of his older newsletters, including FDA Trader, were published directly under the Agora Financial name.
Is Ray Blanco’s Catalyst Trader worth the price?
That depends on your risk tolerance and how much value you place on speculative, event-driven biotech picks. Subscriber ratings on independent review sites are mixed to below-average, so it’s worth reading current reviews and checking the refund terms before you commit to a full year.
Can I get a refund if I’m not happy with the service?
Refund and guarantee terms vary by service and have changed over time, and some subscriptions are explicitly sold as non-refundable. Always read the specific terms on the order page before you subscribe, since the guarantee described in older FDA Profit Alert marketing may not apply to current offers.
Is Ray Blanco connected to Agora Financial or Jim Rickards?
Yes. Blanco has published under the Agora Financial network since 2010 and now works through Paradigm Press, an Agora imprint. He currently co-edits a service with Jim Rickards and James Altucher.
